Related Experiment Video
Updated: May 12, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3
Chuandong Geng1, Bin He, Limei Xu
1Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Abstract:
The p160 steroid receptor coactivators (SRCs) SRC-1, SRC-2 [nuclear receptor coactivator (NCOA)2], and SRC-3 [amplified in breast cancer 1 (AIB1)/NCOA3] are key pleiotropic "master regulators" of transcription factor activity necessary for cancer cell proliferation, survival, metabolism, and metastasis. SRC overexpression and overactivation occur in numerous human cancers and are associated with poor clinical outcomes and resistance to therapy. In prostate cancer (PC), the p160 SRCs play critical roles in androgen receptor transcriptional activity, cell proliferation, and resistance to androgen deprivation therapy. We recently demonstrated that the E3 ubiquitin ligase adaptor speckle-type poxvirus and zinc finger (POZ) domain protein (SPOP) interacts directly with SRC-3 and promotes its cullin 3-dependent ubiquitination and proteolysis in breast cancer, thus functioning as a potential tumor suppressor. Interestingly, somatic heterozygous missense mutations in the SPOP substrate-binding cleft recently were identified in up to 15% of human PCs (making SPOP the gene most commonly affected by nonsynonymous point mutations in PC), but their contribution to PC pathophysiology remains unknown. We now report that PC-associated SPOP mutants cannot interact with SRC-3 protein or promote its ubiquitination and degradation. Our data suggest that wild-type SPOP plays a critical tumor suppressor role in PC cells, promoting the turnover of SRC-3 protein and suppressing androgen receptor transcriptional activity. This tumor suppressor effect is abrogated by the PC-associated SPOP mutations. These studies provide a possible explanation for the role of SPOP mutations in PC, and highlight the potential of SRC-3 as a therapeutic target in PC.
Insights
Prostate cancer (PC) mutations in SPOP disrupt its interaction with SRC-3, preventing SRC-3 degradation and promoting cancer growth. Wild-type SPOP acts as a tumor suppressor by degrading SRC-3 in PC cells.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Steroid receptor coactivators (SRCs) are crucial for cancer progression.
- SRC-3 is implicated in various cancers, including prostate cancer (PC).
- SPOP mutations are common in PC, but their role is unclear.
Purpose of the Study:
- To investigate the role of SPOP and its PC-associated mutants in regulating SRC-3.
- To elucidate the mechanism by which SPOP mutations contribute to PC pathophysiology.
Main Methods:
- Co-immunoprecipitation assays to assess SPOP-SRC-3 interaction.
- Western blotting to evaluate SRC-3 protein levels and ubiquitination.
- Androgen receptor transcriptional activity assays.
Main Results:
- PC-associated SPOP mutants fail to bind SRC-3.
- Mutant SPOP cannot induce SRC-3 ubiquitination and degradation.
- Wild-type SPOP suppresses androgen receptor activity by promoting SRC-3 turnover.
Conclusions:
- Wild-type SPOP functions as a tumor suppressor in PC by degrading SRC-3.
- PC-associated SPOP mutations abrogate this tumor suppressor function.
- Targeting SRC-3 may be a therapeutic strategy for PC.
Related Concept Videos
Regulation of Nuclear Protein Sorting
Spontaneous and Induced Mutations
Abnormal Proliferation
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
RNA Splicing

